Patient stories

      Test
      Focus Area
      Format
      Evidence
FILTER BY TESTS
DecisionDx-Melanoma DecisionDx-SCC MyPath Melanoma TissueCypher DecisionDx-UM IDgenetix

Melanoma diagnosis, now what?

Melanoma is one of the most common cancers found among adults, aged 15-29, in the U.S. and the deadliest if not caught early. There are emerging technologies to help identify a patient’s risk for recurrence and metastasis such as gene expression profiling. Learn about DecisionDX-Melanoma, which is a predictive test to help patients make the most informed treatment decisions.

Cutaneous Melanoma DecisionDx-Melanoma
View More Link icon

From Fear to Confidence: DecisionDx-Melanoma. Greg’s Story of Empowerment Over a Melanoma Diagnosis

Discover Greg’s inspiring journey from a cancer diagnosis to a life of outdoor adventures, empowered by the DecisionDx-Melanoma test. Follow his path to knowledge and resilience in the face of melanoma.

Cutaneous Melanoma DecisionDx-Melanoma
View More Link icon

Don't let fear define your journey: a uveal melanoma patient journey

Danet didn’t let fear of the unknown define her uveal melanoma journey. Hear how Castle Biosciences DecisionDx-UM test impacted her treatment.

Uveal Melanoma DecisionDx-UM
View More Link icon
Click to play "Be Your Own Advocate: Morgan England, Stage III Melanoma Survivor, Shares Her Story" video

Be your own advocate: Morgan England, Stage III melanoma survivor, shares her story

As a Stage III Melanoma survivor, Morgan speaks on how important it is to be your own advocate. After her diagnosis, she requested the DecisionDx-Melanoma test from her doctor for the additional information it can provide. The results she received from her DecisionDx-Melanoma test report continue to help reduce her anxiety and provide confidence about her future.

Cutaneous Melanoma DecisionDx-Melanoma
View More Link icon
Click to play "Castle Biosciences: Our Story" video

Castle Biosciences: Our Story

A closer look into Castle Biosciences: our 'why,' the mission driving our company, and the incredible people dedicated to improving patient care each and every day.

View More Link icon
Click to play "DecisionDx-Melanoma Helps to Guide Patient Management Decisions" video

DecisionDx®-Melanoma Helps to Guide Patient Management Decisions

Dr. Aaron Farberg speaks about how the DecisionDx-Melanoma test results helps better identify a patient's risk of metastasis and how some patients may be able to forgo a SLNB procedure.

DecisionDx-Melanoma
Watch Story Link icon
Click to play "DecisionDx-Melanoma Increases the Risk Prediction that is Currently Available for Patients" video

DecisionDx®-Melanoma Increases the Risk Prediction that is Currently Available for Patients

Dr. Clay Cockerell speaks on how the DecisionDx-Melanoma test is not intended to replace staging systems but how using GEP can increase risk prediction for patients with Stage I-III melanoma.

DecisionDx-Melanoma
Watch Story Link icon
Click to play "Interview and Research Highlights with Dr. Jacques Bergman" video

Interview and Research Highlights with Dr. Jacques Bergman

Dr. Bergman (Amsterdam University Medical Centers) discusses his latest research into tools for risk stratification of patients with community-based diagnosis of low-grade dysplasia.

Barrett's Esophagus TissueCypher
Watch Story Link icon
Click to play "Interview with Dr. Lucas C. Duits: Standardizing Patient Management with TissueCypher" video

Interview with Dr. Lucas C. Duits: Standardizing Patient Management with TissueCypher

This study evaluated the impact that variability in pathologic diagnosis has on patient care and shows that adding guidance from TissueCypher to the standard of care can improve the consistency of management and increase the percentage of progressors that receive appropriate treatment while reducing the number of non-progressors that are over treated.

Barrett's Esophagus TissueCypher
Watch Story Link icon